Anticoagulation-associated Adverse Drug Events

被引:86
|
作者
Piazza, Gregory [1 ]
Thanh Nha Nguyen [2 ]
Cios, Deborah [3 ]
Labreche, Matthew [2 ]
Hohlfelder, Benjamin [2 ]
Fanikos, John [3 ]
Fiumara, Karen [4 ]
Goldhaber, Samuel Z. [1 ]
机构
[1] Harvard Univ, Div Cardiovasc, Dept Med, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Venous Thromboembolism Res Grp, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Ctr Clin Excellence, Boston, MA 02115 USA
来源
AMERICAN JOURNAL OF MEDICINE | 2011年 / 124卷 / 12期
关键词
Adverse drug events; Adverse drug reactions; Anticoagulation; Medication errors; BAR-CODE TECHNOLOGY; ERRORS; THERAPY; SAFETY;
D O I
10.1016/j.amjmed.2011.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs. METHODS: We reviewed all inpatient anticoagulant-associated ADEs, including adverse drug reactions (ADRs) and medication errors, reported at Brigham and Women's Hospital through the Safety Reporting System from May 2004 to May 2009. We also collected data about the cost associated with hospitalizations in which ADRs occurred. RESULTS: Of 463 anticoagulant-associated ADEs, 226 were medication errors (48.8%), 141 were ADRs (30.5%), and 96 (20.7%) involved both a medication error and ADR. Seventy percent of anticoagulant-associated ADEs were potentially preventable. Transcription errors (48%) were the most frequent root cause of anticoagulant-associated medication errors, while medication errors (40%) were a common root cause of anticoagulant-associated ADRs. Death within 30 days of anticoagulant-associated ADEs occurred in 11% of patients. After an anticoagulant-associated ADR, most hospitalization expenditures were attributable to nursing costs (mean $33,189 per ADR), followed by pharmacy costs (mean $7451 per ADR). CONCLUSION: Most anticoagulant-associated ADEs among inpatients result from medication errors and are, therefore, potentially preventable. We observed an elevated 30-day mortality rate among patients who suffered an anticoagulant-associated ADE and high hospitalization costs following ADRs. Further quality improvement efforts to reduce anticoagulant-associated medication errors are warranted to improve patient safety and decrease health care expenditures. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 1136-1142
引用
收藏
页码:1136 / 1142
页数:7
相关论文
共 50 条
  • [21] Long-Term Outcome of Resuming Anticoagulation Treatment After Anticoagulation-Associated Intracerebral Hemorrhage.
    Beckett, Lisa
    DiCristina, Heather
    Wagner, Thomas
    Wright, Kathryn
    Capone, Kellie
    Monczewski, Maureen
    Kester, Margaret
    Bourdages, George
    Zand, Ramin
    STROKE, 2019, 50
  • [22] Database of adverse events associated with drugs and drug combinations
    Aleksandar Poleksic
    Lei Xie
    Scientific Reports, 9
  • [23] Fluoroquinolone use and associated adverse drug events in England
    Baddour, Larry M.
    Dayer, Mark J.
    Thornhill, Martin H.
    JOURNAL OF INFECTION, 2019, 78 (03) : 251 - 253
  • [24] Update on adverse drug events associated with parenteral iron
    Chertow, GM
    Mason, PD
    Vaage-Nilsen, O
    Ahlmén, J
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) : 378 - 382
  • [25] Database of adverse events associated with drugs and drug combinations
    Poleksic, Aleksandar
    Xie, Lei
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [26] Anticoagulation-associated bleeding in patients randomised to screening for atrial fibrillation or usual care
    Kongebro, E.
    Diederichsen, S.
    Xing, L.
    Haugan, K.
    Graff, C.
    Hoejberg, S.
    Olesen, M.
    Brandes, A.
    Koeber, L.
    Svendsen, J.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [27] Apolipoprotein E Genotype Predicts Anticoagulation-associated Intracerebral Hemorrhage Recurrence.
    Urday, Sebastian
    Biffi, Alessandro
    Rodriguez-Torres, Axana
    Pasi, Marco
    Kourkoulis, Christina
    Schwab, Kristin
    Greenberg, Steven M.
    Viswanathan, Anand
    Gurol, M. Edip
    Sheth, Kevin N.
    Anderson, Christopher
    Rosand, Jonathan
    STROKE, 2019, 50
  • [28] Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation
    Vasileios-Arsenios Lioutas
    Nitin Goyal
    Aristeidis H. Katsanos
    Christos Krogias
    Ramin Zand
    Vijay K. Sharma
    Panayiotis Varelas
    Konark Malhotra
    Maurizio Paciaroni
    Theodore Karapanayiotides
    Aboubakar Sharaf
    Jason Chang
    Odysseas Kargiotis
    Abhi Pandhi
    Lina Palaiodimou
    Christoph Schroeder
    Argyrios Tsantes
    Efstathios Boviatsis
    Chandan Mehta
    Aspasia Serdari
    Konstantinos Vadikolias
    Panayiotis D. Mitsias
    Magdy H. Selim
    Andrei V. Alexandrov
    Georgios Tsivgoulis
    Journal of Neurology, 2020, 267 : 1053 - 1062
  • [29] The Role of Hemostatic Therapy in Anticoagulation-Associated Intracerebral Hemorrhage Intuition Versus Evidence
    Selim, Magdy H.
    Molina, Carlos A.
    STROKE, 2012, 43 (09) : 2539 - 2540
  • [30] Blood Pressure and Anticoagulation Reversal Management during Off-Hours in Oral Anticoagulation-Associated Intracerebral Hemorrhage
    Mrochen, Anne
    Spruegel, Maximilian I.
    Gerner, Stefan T.
    Sembill, Jochen A.
    Lang, Stefan
    Luecking, Hannes
    Kuramatsu, Joji B.
    Huttner, Hagen B.
    CEREBROVASCULAR DISEASES, 2020, 49 (02) : 177 - 184